Association of long-term PPI use with low-risk gastric neuroendocrine tumor

#4234

Introduction: Gastric neuroendocrine tumors are rare neoplasms, comprising approximately 2% of all gastric tumors, and develop from enterochromaffin-like (ECL) cells in the gastric mucosa. Type I and II develop due to hypergastrinemia and ECL cell hyperplasia; type III typically occurs sporadically, tend to be more aggressive, present metastatically in > 50% of cases, have normal fasting gastrin levels, and vary histopathologically from well- to poorly differentiated.

Aim(s): While long-term proton pump inhibitor (PPI) use has been known to lead to chronic hypergastrinemia, only a few cases of gastric NETs associated with PPI use are reported, and the classification of these cases remains undefined.

Materials and methods: Retrospective study of all gastric NETs seen at MCC between 1/2008 and 8/2023. Type I and II gastric carcinoids, and poorly differentiated NECs were excluded. Data was collected on pts with type 3 gastric NETs, including PPI use, gastrin levels, pathologic features, and presence of metastatic disease.

Conference:

Presenting Author: Al-Toubah T

Authors: Al-Toubah T, Pelle E, Haider M, Strosberg J,

Keywords: gastric, ppi, neuroendocrine, type 3 gastric net,